Evidence map›Paper›PMID 35203573›Full record

ArticleBiomedicines2022

AAV-Vectored Expression of the Vascular Normalizing Agents 3TSR and Fc3TSR, and the Anti-Angiogenic Bevacizumab Extends Survival in a Murine Model of End-Stage Epithelial Ovarian Carcinoma.

Ashley A Stegelmeier, Lisa A Santry, Matthew M Guilleman, Kathy Matuszewska, Jessica A Minott, Jacob G E Yates, Brenna A Y Stevens, Sylvia P Thomas, Sierra Vanderkamp, Kiersten Hanada and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. AAV for ovarian cancer gene therapy.Cancer gene therapy · 2025
    Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Ashley A StegelmeierDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.ORCID 0000-0002-2296-8288
Lisa A SantryDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Matthew M GuillemanDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Kathy MatuszewskaDepartment of Biomedical Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada.
Jessica A MinottDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.ORCID 0000-0002-2065-1869
Jacob G E YatesDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Brenna A Y StevensDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Sylvia P ThomasDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Sierra VanderkampDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Kiersten HanadaDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Yanlong PeiDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Amira D RgheiDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Jacob P van VlotenDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.
Madison PereiraDepartment of Biomedical Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada.ORCID 0000-0002-4902-1983
Brad ThompsonAvamab Pharma Inc., Calgary, AB T3E 6L1, Canada.
Pierre P MajorJuravinski Cancer Centre, 699 Concession Street, Hamilton, ON L8V 5C2, Canada.
James J PetrikDepartment of Biomedical Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada.ORCID 0000-0001-7102-637X
Byram W BridleDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.ORCID 0000-0002-8335-1118
Sarah K WoottonDepartment of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada.ORCID 0000-0002-5985-2406
University of Guelph · CAJuravinski Cancer Centre · CA

Funding

Canadian Scientific Research and Experimental Development Program NANatural Sciences and Engineering Research Council of Canada through a Discovery Grant 355661
6 · The paper itself

Abstract

Epithelial ovarian cancer is the deadliest gynecological malignancy. The lack of effective treatments highlights the need for novel therapeutic interventions. The aim of this study was to investigate whether sustained adeno-associated virus (AAV) vector-mediated expression of vascular normalizing agents 3TSR and Fc3TSR and the antiangiogenic monoclonal antibody, Bevacizumab, with or without oncolytic virus treatment would improve survival in an orthotopic syngeneic mouse model of epithelial ovarian carcinoma. AAV vectors were administered 40 days post-tumor implantation and combined with oncolytic avian orthoavulavirus-1 (AOaV-1) 20 days later, at the peak of AAV-transgene expression, to ascertain whether survival could be extended. Flow cytometry conducted on blood samples, taken at an acute time point post-AOaV-1 administration (36 h), revealed a significant increase in activated NK cells in the blood of all mice that received AOaV-1. T cell analysis revealed a significant increase in CD8

Indexed as

adeno-associated virus (AAV)AOaV-1gene therapyoncolytic virotherapyovarian cancervascular normalization

Identifiers

PMID35203573
PMCPMC8962366
OpenAlexW4210346055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.